To test whether EVs could render tumors susceptible to immune checkpoint therapy, mice were engrafted with OVA-expressing B16 melanoma cells and, when tumors were palpable, treated with EVs, anti–PD-1/anti–PD-L1, or combination therapy (Fig. 2A). Here, PDCD1 is linked to melanoma.